# A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

> **NCT02411136** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 64 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** AMG 623
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02411136
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-08
- **Final completion:** 2007-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02411136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02411136, "A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02411136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*